小儿激素耐药型肾病综合征的发病机制及临床诊治研究进展被引量：2

下载PDF

导出

摘要激素耐药型肾病综合征（SRNS）是一种临床表现为低白蛋白血症、尿中含大量蛋白及高胆固醇血症的疾病。目前关于SRNS诊断标准、发病机制及临床诊断在国内外仍存在一定的争议,本研究将以综述的方式对目前SRNS临床研究进展作一概述,旨在为临床SRNS临床诊治提供新的指导思想。1 SRNS临床发病机制目前引起SRNS的临床因素较多,其发病机制复杂,近年越来越多的研究显示,

作者黄琴何庆南

机构地区中南大学湘雅二医院长沙市第一医院

出处《湖北科技学院学报（医学版）》 2014年第5期455-458,共4页 Journal of Hubei University of Science and Technology(Medical Sciences)

关键词激素耐药型肾病综合征发病机制临床诊治

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献25

1易玲,任榕娜,余自华.环孢素治疗激素耐药型肾病综合征的研究进展[J].实用儿科临床杂志,2012,27(5):371-374. 被引量：14
2余自华,易玲.中国与印度儿童激素耐药型肾病综合征诊治指南比较[J].实用儿科临床杂志,2012,27(17):1375-1376. 被引量：1
3王亭,吴滢,何威逊,朱光华.儿童激素耐药型肾病综合征与CD2相关蛋白基因启动子突变的相关性[J].实用儿科临床杂志,2011,26(17):1325-1327. 被引量：6
4Zalewski G,Wasilewska A,Zoch-Zwierz W,et al.Response toprednisone in relation to NR3C1 intron B polymorphisms inchildhood nephrotic syndrome[J].Pediatr Nephrol,2008,23(7):1073.
5张瑶,于力,于生友.广东地区原发性激素耐药型肾病综合征患儿NPHS2、CD2AP基因突变筛查[J].中华实用儿科临床杂志,2013,28(5):341-344. 被引量：7
6Sato H,Sugiyama H,Yokoyama H.Epidemiology of nephrotic syndrome in Japan[J].Nihon Jinzo Gakkai Shi,2014,56(4):464.
7Muso E1,Mune M,Hirano T,et al.Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome:evidence from the short-term results from the POLARIS Study[J].Clin Exp Nephrol,2014,12(7):196.
8李少军,李秋,阳海平,陶红,范忠祥,李国安.环磷酰胺冲击治疗儿童激素耐药型肾病综合征的疗效[J].实用儿科临床杂志,2011,26(17):1358-1360. 被引量：16
9Trebble PJ,Woolven JM,Saunders KA,et al.A ligand·specific kinetic switch regulates glucocorticoid receptor trafficking and function[J].J Cell Sci,2013,126(17):3159.
10D'Attilio L,Trini E,Bongiovanni B,e al.mRNA expression ofalpha and beta isoforms of glucocorticoid receptor in peripheral blood mononuclear cells of patients with tuberculosis and its relation witll components of the immunoendocrine response[J].Brain Behav Immun,2011,25(3):461.

二级参考文献73

1余自华,丁洁.肾病综合征激素耐药与NPHS2基因[J].中华儿科杂志,2005,43(2):154-156. 被引量：11
2叶礼燕,郑智勇,余自华,夏桂枝,王承峰,陈光明,黄隽,任榕娜,陈新民,黄祖雄.小儿肾活检244例临床与病理分析[J].临床儿科杂志,2005,23(2):108-109. 被引量：2
3潘晓霞,陈楠,周伟,王朝晖,张文,王伟铭,陈晓农,巫永睿,陆颖.原发性局灶节段性肾小球硬化患者CD2AP基因突变的研究[J].中华肾脏病杂志,2006,22(1):13-18. 被引量：24
4Mekahli D, Liutkus A, Ranchin B, et al. Long - term outcome of idio- pathic steroid - resistant nephritic syndrome: A multicenter study [ J ]. Pediatr Nephrol,2009,24(8) :1525 - 1532.
5Mao J, Zhang Y, Du L,et al. Expression profile of nephrin, podocin, and CD2AP in Chinese children with MCNS and IgA nephropathy [ J ]. Pediatr Nephrol, 2006,21 ( 11 ) : 1666 - 1675.
6Lu C,Ren W,Su XM,et al. CREB and Spl regulate the human CD2AP gene promoter activity in renal tubular epithelial cells[ J ]. Arch Biochem Biophys,2008,474 ( 1 ) :143 - 149.
7Benoit G, Machuca E, Nevo F, et al. Analysis of recessive CD2AP and ACTN4 mutations in steroid - resistant nephrotic syndrome [ J ]. Pediatr Nephro1,2010,25 ( 3 ) :445 - 451.
8Gellermann J, Stefanidis C J, Mitsioni A et al. Successful treatment of steroid -resistant nephrotic syndrome associated with WTI mutations [ J ]. Pediatr Nephro1,2010,25 (7) : 1285 - 1289.
9Taylor A, Verhagen J, Akkoc T,et al. IL - 10 suppresses CD2 -mediated T cell activation via SHP- 1 [ J ]. Mol Immuno1,2009,46 (4) :622 -629.
10Xavier S, Niranjan T, Krick S,et al. TI3RI independently activates Smad - and CD2AP - dependent pathways in podocytes [ J ]. J Am Soc Nephrol, 2009,20(10) :2127 -2137.